About us

BioMedBC MSCA Fellow: Dr. Maria Frantzi

BioMedBC Fellow: Maria Frantzi

Maria Frantzi received a MSc (2012) and a PhD (2016) in Molecular Medicine from Athens Medical School.

During her PhD studies, she received a Marie Skłodowska-Curie fellowship, during which she shared her time

between University of Glasgow (UK), Biomedical Research Foundation of Academy of Athens (BRFAA, Greece)

and Mosaiques diagnostics GmbH (Germany). She currently performs research in the context of BioMedBC

with main focus on proteomics, cancer diagnostic and stratification biomarkers. Through the post-doctoral BioMedBC

MSCA fellowship, she has expanded her research towards personalized medicine and

-omics data integration. This is achieved through the application of proteomics technologies

and system biology for investigating disease pathophysiology and molecularly driven drug targets.




Host Institution

Mosaiques Diagnostics GmbH (SME)



mosaiques diagnostics GmbH (SME) is established in Hannover, Germany

The company’s core competence is the early and reliable detection of diseases enabling personalized medicine

during therapy and drug development. The company utilizes diagnostic polypeptide patterns derived from the

fast and accurate analysis of proteins and polypeptides in body fluids (e.g. urine, bile and cerebrospinal fluid).

Mosaiques Diagnostics GmbH has developed and is the leading specialist in clinical proteome and CE-MS analysis,

currently the best technology available for identifying disease-specific polypeptide biomarkers in body fluids.

MOS has published over 120 papers in peer-reviewed journals on its proprietary technology with more than 4,500

citations and filed over 100 patent applications, further underlining the leading role of this European SME.

MOS has developed proprietary hardware for analysis and software solutions for data evaluation, and owns

a unique and proprietary database of peptides in human body fluids of currently 50,000 samples.

MOS has ample experience in clinical studies, and is engaged in collaborative projects with regulatory agencies.

In addition, MOS has filed for qualification of multiparametric proteomics-based classifiers as

biomarkers for human disease with the relevant regulatory agencies (EMA and FDA).

BioMedBC is a Marie Sklodowska Curie Actions (MSCA) Individual Fellowship programme (H2020-MSCA-IF-2016)
funded by the European Union under the Horizon2020 Framework Programme (Grant Agreement:752755) and
coordinated by Mosaiques diagnostics